SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS
申请人:BLUM Andreas
公开号:US20150005278A1
公开(公告)日:2015-01-01
This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I
wherein Ar, R
1
and R
2
are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.
THE REACTION OF 2,2-DIMETHYL-4-LITHIO-1,3-OXATHIANE 3,3-DIOXIDE. GENERAL SYNTHESIS OF γ-HYDROXYKETONES
作者:Kaoru Fuji、Manabu Node、Yoshihide Usami
DOI:10.1246/cl.1986.961
日期:1986.6.5
Reactions of 2,2-dimethyl-4-lithio-1,3-oxathiane 3,3-dioxide (2) with alkyl halides and carbonyl compounds proceed smoothly to give 4-substituted heterocycles. A general synthesis of γ-hydroxyketones from aldehydes utilizing 2 is described.
The present invention concerns novel pharmaceutically active triterpene derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C2-8 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus (HIV).